臨床神経学

<シンポジウム(2)―9―4>神経疾患iPS細胞の現状と展望

脳梗塞への再生医療とiPS細胞移植療法

阿部 康二, 山下 徹, 河相 裕美

岡山大学脳神経内科〔〒700―8558 岡山県岡山市北区鹿田町2―5―1〕

Stroke is a major neurologic disorder. Induced pluripotent stem (iPS) cells can be produced from basically any part of patients, with high reproduction ability and pluripotency to differentiate into various types of cells, suggesting that iPS cells can provide a hopeful therapy for cell transplantation. However, transplantation of iPS cells into ischemic brain has not been reported. In this study, we showed that the iPS cells fate in a mouse model of transient middle cerebral artery occlusion (MCAO). Undifferentiated iPS cells (5∗10(5)) were transplanted into ipsilateral striatum and cortex at 24 h after 30 mins of transient MCAO. Behavioral and histologic analyses were performed at 28 day after the cell transplantation. To our surprise, the transplanted iPS cells expanded and formed much larger tumors in mice postischemic brain than in sham-operated brain. The clinical recovery of the MCAO+iPS group was delayed as compared with the MCAO+PBS (phosphate-buffered saline) group. iPS cells formed tridermal teratoma, but could supply a great number of Dcx-positive neuroblasts and a few mature neurons in the ischemic lesion. iPS cells have a promising potential to provide neural cells after ischemic brain injury, if tumorigenesis is properly controlled.
Full Text of this Article in Japanese PDF (366K)

(臨床神経, 52:1143−1146, 2012)
key words:iPS細胞,脳梗塞,山中4因子,MMP9

(受付日:2012年5月24日)